mrpl-23 Antibody

What is MRPL23 and what is its biological significance?

MRPL23 is a mitochondrial ribosomal protein that forms part of the large subunit of the mitochondrial ribosome (mitoribosome). It plays a crucial role in protein synthesis within mitochondria, directly affecting cellular energy production and metabolic processes. Recent research has demonstrated that MRPL23 expression is notably altered in several cancer types, particularly in clear-cell renal cell carcinoma (ccRCC), where its protein expression is significantly reduced in tumor tissues compared to adjacent non-tumorous tissues, while its mRNA levels are paradoxically elevated . This discrepancy suggests complex post-transcriptional regulation mechanisms that warrant further investigation. MRPL23's involvement in mitochondrial function makes it particularly relevant to cancer metabolism research, as mitochondrial dysregulation is a recognized hallmark of cancer progression.

What is the relationship between MRPL23 and MRPL23-AS1?

MRPL23-AS1 is a long non-coding RNA (lncRNA) that is associated with the MRPL23 gene locus. While MRPL23 is a protein-coding gene, MRPL23-AS1 functions as a regulatory non-coding RNA. Research indicates that MRPL23-AS1 plays significant roles in tumor progression through various mechanisms independent of MRPL23 protein function . MRPL23-AS1 has been shown to influence cancer cell behavior by modulating signaling pathways, particularly through interactions with microRNAs. In some studies, MRPL23-AS1 has been demonstrated to interact with miR-30b and regulate the Wnt/β-catenin signaling pathway, influencing tumor development . Furthermore, MRPL23-AS1 has been implicated in promoting lung metastasis in adenoid cystic carcinoma . The distinct but potentially complementary functions of MRPL23 protein and MRPL23-AS1 underscore the complexity of this genetic locus in cancer biology.

What immunohistochemistry protocols yield optimal results for MRPL23 antibody staining?

For optimal MRPL23 antibody staining in immunohistochemistry (IHC), researchers should implement a standardized protocol that maximizes specificity while minimizing background staining. Based on established methodologies, the following approach is recommended:

• Tissue preparation: Formalin-fixed, paraffin-embedded (FFPE) tissue sections should be cut at 4-5 μm thickness and mounted on positively charged slides.

• Antigen retrieval: Heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) for 20 minutes has shown optimal results. This step is critical as it unmasks epitopes potentially altered during fixation.

• Blocking: A 5-10% normal serum blocking step (30 minutes at room temperature) minimizes non-specific binding.

• Primary antibody incubation: MRPL23 antibody should be applied at an optimized concentration (typically 1:100 to 1:500 dilution depending on the specific antibody) and incubated overnight at 4°C or for 1-2 hours at room temperature .

• Detection system: A polymer-based detection system typically yields cleaner results than avidin-biotin methods, with 3,3'-diaminobenzidine (DAB) as the chromogen.

• Counterstaining: Light hematoxylin counterstaining for 30-60 seconds allows visualization of tissue architecture without obscuring specific MRPL23 staining.

Following this protocol, MRPL23 typically displays cytoplasmic localization in positive cells, consistent with its mitochondrial function . Standardization of these parameters is essential for comparable results across different studies.

How should MRPL23 antibody staining results be quantified?

Accurate quantification of MRPL23 immunostaining is critical for research reproducibility and meaningful clinical correlations. The Index Remmele–Stegner scale (IRS) has proven effective for MRPL23 quantification, providing a nuanced assessment of both staining intensity and percentage of positive cells . This approach involves:

• Percentage scoring: Evaluate the percentage of positively stained cells using a 0-4 scale:

  • 0: No positive cells

  • 1: Less than 10% of cells positive

  • 2: 10–50% of cells positive

  • 3: 51–80% of cells positive

  • 4: More than 80% of cells positive

• Intensity scoring: Assess staining intensity on a 0-3 scale:

  • 0: Negative

  • 1: Weak staining

  • 2: Moderate staining

  • 3: Strong staining

• IRS calculation: Multiply the percentage score (0-4) by the intensity score (0-3) to obtain a final IRS value ranging from 0-12.

• Expression categorization: Using statistical tools such as the Evaluate Cutpoints program, determine the optimal cutoff value to stratify samples into "high" and "low" expression groups .

For digital image analysis, whole slide imaging using systems such as the Roche Ventana DP 200 scanner can provide standardized input for computer-assisted quantification, reducing inter-observer variability . This systematic approach to quantification facilitates meaningful comparison of MRPL23 expression across diverse sample cohorts.

What controls are essential when working with MRPL23 antibodies?

Implementing appropriate controls is critical for ensuring the validity and reliability of MRPL23 antibody-based experiments. The following controls should be included:

• Positive tissue controls: Tissues with known MRPL23 expression profiles should be included in each staining batch. Renal tubular epithelial cells in normal kidney tissue demonstrate consistent MRPL23 expression and serve as excellent positive controls .

• Negative controls: Primary antibody omission on duplicate sections validates detection system specificity. Additionally, tissues known to have minimal MRPL23 expression should be included as biological negative controls.

• Isotype controls: Inclusion of sections treated with isotype-matched non-specific immunoglobulins at equivalent concentrations to the primary antibody helps distinguish specific binding from Fc receptor-mediated or other non-specific interactions.

• Antibody validation controls: Western blot analysis using cell lines with confirmed MRPL23 expression versus those with MRPL23 knockdown or knockout should be performed to verify antibody specificity before immunohistochemical applications.

• Internal control tissues: When examining pathological specimens, adjacent non-tumorous tissue provides an internal reference for normal expression patterns, as demonstrated in studies comparing MRPL23 expression between ccRCC and adjacent normal tissues .

These comprehensive controls enable confident interpretation of MRPL23 immunostaining results and facilitate troubleshooting if unexpected staining patterns emerge.

How can researchers investigate contradictions between MRPL23 protein and mRNA expression?

The observed discrepancy between MRPL23 protein levels (decreased in ccRCC) and mRNA levels (increased in ccRCC) represents an intriguing research question requiring multifaceted investigation . Researchers exploring this contradiction should consider the following methodological approaches:

• Multi-omics integration: Combine proteomics, transcriptomics, and potentially ribosome profiling to comprehensively map expression dynamics. Quantitative proteomics has proven particularly valuable in characterizing MRPL gene-disease associations .

• Post-transcriptional regulation analysis: Examine microRNA-mediated regulation by:

  • Identifying miRNAs with predicted binding sites in MRPL23 mRNA

  • Performing RNA immunoprecipitation followed by sequencing (RIP-seq) to isolate MRPL23-associated miRNAs

  • Validating interactions through luciferase reporter assays similar to those used for MRPL23-AS1 studies

• Protein stability assessment: Compare MRPL23 protein half-life in normal versus cancer cells using cycloheximide chase assays coupled with western blotting at multiple time points.

• RNA-binding protein analysis: Investigate whether RNA-binding proteins differentially interact with MRPL23 transcripts in tumor versus normal tissues using RNA pull-down assays followed by mass spectrometry.

• Alternative splicing detection: Employ RT-PCR with primers spanning multiple exons to identify potential cancer-specific MRPL23 isoforms that might affect protein stability or antibody detection, similar to approaches used in MRPL39 studies .

This multi-method approach can elucidate the mechanisms underlying the protein-mRNA discrepancy and potentially reveal novel cancer-specific regulatory pathways.

What techniques are most effective for studying MRPL23's role in mitoribosome assembly?

Investigating MRPL23's role in mitoribosome assembly requires specialized techniques that preserve the integrity of these complex molecular structures. The following methodological approaches have proven effective:

• Density gradient ultracentrifugation: Separate intact mitoribosomes, large subunits (mtLSU), and small subunits (mtSSU) on sucrose gradients (10-30%) to assess the impact of MRPL23 alterations on ribosome assembly.

• Quantitative proteomics: Apply methods like Relative Complex Abundance analysis to detect subtle changes in mitoribosomal protein composition with high sensitivity. This approach has successfully identified defects in OXPHOS disorders and can detect complex assembly disruptions in rare diseases .

• Cryo-electron microscopy (cryo-EM): Visualize structural alterations in mitoribosomes resulting from MRPL23 deficiency or mutation. This technique provides near-atomic resolution of complex structures without crystallization.

• Proximity labeling: Employ techniques like BioID or APEX2 where MRPL23 is fused to a promiscuous biotin ligase to identify proteins within the immediate vicinity of MRPL23 in living cells, revealing its interaction network within the mitoribosome.

• CRISPR-based functional genomics: Create isogenic cell lines with MRPL23 variants to systematically assess their impact on mitoribosome assembly and function through subsequent proteomic and functional analyses.

When applying these techniques, researchers should ensure mitochondrial isolation procedures maintain the integrity of mitochondrial complexes, typically using gentle detergents and avoiding freeze-thaw cycles that can disrupt native protein interactions.

How can MRPL23 protein-protein interactions be effectively characterized?

Characterizing MRPL23's protein interactions is crucial for understanding its functional role within the mitoribosome and potential moonlighting functions. Several complementary approaches yield comprehensive interaction data:

• Co-immunoprecipitation (Co-IP): Using validated MRPL23 antibodies, researchers can pull down MRPL23 and its interacting partners from cell lysates. Western blot analysis can then confirm interactions with suspected binding partners, while mass spectrometry can identify novel interactors. This approach has been used effectively for mitoribosomal proteins .

• Proximity-dependent biotin identification (BioID): This method involves fusing MRPL23 to a promiscuous biotin ligase (BirA*) that biotinylates proximal proteins, which can then be purified using streptavidin and identified by mass spectrometry.

• Crosslinking mass spectrometry (XL-MS): This technique uses chemical crosslinkers to stabilize transient protein-protein interactions before mass spectrometric analysis, providing both interaction data and spatial constraints.

• Yeast two-hybrid screening: Although this represents a more classical approach, Y2H can identify direct binary interactions between MRPL23 and other proteins, complementing results from methods that capture larger complexes.

• Fluorescence resonance energy transfer (FRET): By tagging MRPL23 and putative interacting proteins with appropriate fluorophores, researchers can monitor real-time interactions in living cells, providing dynamic information about interaction kinetics.

When reporting protein interaction data, researchers should classify interactions as direct (physical contact) or indirect (within the same complex) and validate key interactions through at least two independent methodologies to ensure reliability.

How should researchers interpret survival data in relation to MRPL23 expression?

Interpreting survival data in relation to MRPL23 expression requires careful statistical analysis and consideration of confounding variables. Based on established approaches in MRPL23 research, the following methodology is recommended:

This comprehensive approach has demonstrated that MRPL23 protein expression remains an independent prognostic factor (HR 1.66, 95% CI 1.07–2.56, p = 0.02) even after adjustment for multiple variables, while MRPL23 mRNA expression loses independent significance in multivariate models (HR 1.18, 95% CI 0.85–1.64, p = 0.32) .

Table 1: Univariate and multivariate Cox regression analysis results for MRPL23 mRNA expression in ccRCC patients .

• Interaction analysis: Investigate potential interactions between MRPL23 expression and other clinical variables by including interaction terms in Cox models or performing stratified analyses within specific patient subgroups.

What are the best approaches for validating MRPL23 antibody specificity?

Validating MRPL23 antibody specificity is essential for ensuring reliable research results. A comprehensive validation strategy should include:

• Genetic knockdown/knockout controls: Generate cell lines with MRPL23 knockdown using siRNA/shRNA or knockout using CRISPR-Cas9 technology. Compare antibody signal between control and MRPL23-depleted samples using both western blotting and immunohistochemistry. Complete absence or significant reduction of signal in depleted samples confirms specificity. This approach has been used successfully for validating antibodies against mitoribosomal proteins .

• Immunoblotting validation: Perform western blot analysis using the antibody on various cell types. The detection of a single band at the expected molecular weight (approximately 14.5 kDa for MRPL23) supports specificity. Multiple bands may indicate cross-reactivity or post-translational modifications that require further investigation.

• Peptide competition assay: Pre-incubate the antibody with excess purified MRPL23 protein or immunizing peptide before application to samples. Disappearance of the signal confirms that the antibody is binding specifically to MRPL23 epitopes.

• Mass spectrometry verification: After immunoprecipitation with the MRPL23 antibody, analyze pulled-down proteins by mass spectrometry. Enrichment of MRPL23 peptides confirms antibody specificity.

• Multi-antibody concordance: Compare staining patterns from at least two different MRPL23 antibodies targeting distinct epitopes. Concordant results significantly increase confidence in specificity.

These rigorous validation steps should be performed before using any MRPL23 antibody for quantitative research applications, and validation data should be included in research publications to support methodological transparency.

How can MRPL23 expression data be integrated with other biomarkers for improved prognostic models?

Integrating MRPL23 expression data with other biomarkers can enhance prognostic modeling and potentially lead to more personalized treatment approaches. Researchers should consider the following methodological framework:

• Multivariate biomarker modeling: Combine MRPL23 expression with established prognostic markers using advanced statistical approaches:

  • Cox proportional hazards models with multiple biomarkers

  • Random forest survival analysis

  • Elastic net regularization for feature selection when dealing with many potential biomarkers

• Molecular pathway integration: Analyze MRPL23 in context with other mitoribosomal proteins (MRPLs) and mitochondrial function markers. For example, concurrent analysis of MRPL39 and MRPL15 alongside MRPL23 may provide more comprehensive insights into mitoribosomal dysfunction in cancer .

• Nomogram development: Create clinical nomograms that incorporate MRPL23 expression with traditional prognostic factors (stage, grade, etc.) to generate individualized survival probability estimates. Assess model performance using:

  • Concordance index (C-index) for discrimination

  • Calibration plots for accuracy

  • Decision curve analysis for clinical utility

• Artificial intelligence approaches: Employ machine learning algorithms to identify non-linear relationships between MRPL23 and other biomarkers:

  • Support vector machines

  • Neural networks

  • Gradient boosting methods

• Validation strategies: Implement rigorous validation using:

  • Internal validation (bootstrapping, cross-validation)

  • External validation in independent cohorts

  • Temporal validation with more recent patient cohorts

The effectiveness of such integrated models should be evaluated not only on statistical performance metrics but also on their ability to guide clinical decision-making and improve patient outcomes beyond current prognostic systems.

How might MRPL23 function in cancer cell metabolism be investigated?

Investigating MRPL23's role in cancer metabolism requires approaches that link mitoribosome function to broader metabolic phenotypes. Researchers should consider these methodological strategies:

• Metabolic flux analysis: Apply stable isotope-labeled metabolites (e.g., 13C-glucose, 13C-glutamine) to cells with modulated MRPL23 expression, followed by mass spectrometry to track metabolite fate through various pathways. This approach can reveal how MRPL23 alterations affect carbon routing through glycolysis, TCA cycle, and other pathways.

• Mitochondrial function assessment: Measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using platforms such as Seahorse XF Analyzer in cells with normal versus altered MRPL23 expression to quantify effects on oxidative phosphorylation and glycolysis.

• Mitochondrial protein synthesis assay: Pulse-label cells with 35S-methionine in the presence of cytoplasmic translation inhibitors (e.g., cycloheximide) to specifically assess mitochondrial translation capacity in relation to MRPL23 expression.

• In-organello translation: Isolate mitochondria from cells with differential MRPL23 expression and perform translation assays in the isolated organelles to directly assess mitochondrial protein synthesis capacity.

• Integrated multi-omics: Combine transcriptomics, proteomics, and metabolomics data to create comprehensive metabolic network models that elucidate how MRPL23-related mitoribosomal dysfunction propagates through cellular metabolism.

These complementary approaches can establish causal relationships between MRPL23 expression, mitoribosome function, and the metabolic reprogramming characteristic of cancer cells.

What are the best methods for studying interactions between MRPL23 and MRPL23-AS1?

Investigating potential functional relationships between MRPL23 protein and its associated long non-coding RNA MRPL23-AS1 requires specialized techniques that span RNA-protein interactions and regulatory networks:

• RNA immunoprecipitation (RIP): Using validated MRPL23 antibodies, perform RIP followed by qRT-PCR or sequencing to determine if MRPL23 protein physically interacts with MRPL23-AS1 or other RNAs. This approach would help determine if there is direct regulatory feedback.

• RNA pull-down assays: Synthesize biotinylated MRPL23-AS1 RNA using in vitro transcription kits (e.g., MEGA scriptTM T7), incubate with cell lysates, and identify interacting proteins through mass spectrometry. This technique has been successfully applied with MRPL23-AS1 to identify interaction partners .

• Co-expression analysis: Perform simultaneous quantification of MRPL23 protein (by western blot/IHC) and MRPL23-AS1 (by qRT-PCR) across multiple cell lines and tissue samples to identify correlated expression patterns suggestive of co-regulation.

• Dual modulation studies: Implement concurrent manipulation of both MRPL23 and MRPL23-AS1 levels using:

  • shRNA knockdown of MRPL23-AS1 (e.g., using sequences like 5'-CACAGCGCUGAGAAAGUAA-3') combined with MRPL23 overexpression/knockdown

  • CRISPR-Cas9 targeted disruption of regulatory elements

  • Analyze phenotypic outcomes to identify synergistic or antagonistic effects

• Subcellular co-localization: Employ RNA fluorescence in situ hybridization (FISH) for MRPL23-AS1 combined with immunofluorescence for MRPL23 protein to assess spatial co-localization within cellular compartments.

These approaches can illuminate the potentially complex regulatory relationship between MRPL23 and MRPL23-AS1, advancing our understanding of how coding and non-coding elements of the genome cooperate in cancer development.